Apply to trial NCT06622174

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 1Radiation therapy

Pulse Radiotherapy to Overcome Metastatic Immune System Evasion in Lung Cancer

This phase I study aims to evaluate the safety and effectiveness of adaptive pulsed radiotherapy combined with immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC) resistant to immune checkpoint inhibitors. The primary goal is to assess treatment-related toxicity, while secondary objectives include progression-free survival, overall survival, and quality of life. The study will enroll 32 patients.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Pulse Radiotherapy to Overcome Metastatic Immune System Evasion in Lung Cancer

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening